XML 79 R68.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Jan. 31, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | $ 10,325 | $ 10,536 | $ 29,689 | $ 29,692
Proceeds from sale of marketing rights |  |  |  | 60 | 75
Corticotropin marketing rights |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Proceeds from sale of marketing rights | $ 75 |  |  |  |
Operating Segments |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 10,256 | 10,420 | 29,289 | 29,109
Operating Segments | Total Pharmaceutical segment sales |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 9,156 | 9,443 | 26,101 | 26,247
Operating Segments | Total Pharmaceutical segment sales | Zetia |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 320 | 671 | 1,021 | 1,985
Operating Segments | Total Pharmaceutical segment sales | Vytorin |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 142 | 273 | 565 | 843
Operating Segments | Total Pharmaceutical segment sales | Atozet |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 59 | 39 | 171 | 96
Operating Segments | Total Pharmaceutical segment sales | Adempas |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 70 | 48 | 221 | 120
Operating Segments | Total Pharmaceutical segment sales | Januvia |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 1,012 | 1,006 | 2,799 | 2,976
Operating Segments | Total Pharmaceutical segment sales | Janumet |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 513 | 548 | 1,572 | 1,624
Operating Segments | Total Pharmaceutical segment sales | NuvaRing |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 214 | 195 | 573 | 571
Operating Segments | Total Pharmaceutical segment sales | Implanon/Nexplanon |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 155 | 148 | 503 | 446
Operating Segments | Total Pharmaceutical segment sales | Follistim AQ |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 72 | 101 | 232 | 268
Operating Segments | Total Pharmaceutical segment sales | Zepatier |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 468 | 164 | 1,363 | 326
Operating Segments | Total Pharmaceutical segment sales | Isentress/Isentress HD |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 310 | 372 | 896 | 1,050
Operating Segments | Total Pharmaceutical segment sales | Bridion |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 185 | 139 | 495 | 343
Operating Segments | Total Pharmaceutical segment sales | Noxafil |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 162 | 147 | 458 | 434
Operating Segments | Total Pharmaceutical segment sales | Invanz |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 159 | 152 | 445 | 409
Operating Segments | Total Pharmaceutical segment sales | Cancidas |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 94 | 142 | 327 | 406
Operating Segments | Total Pharmaceutical segment sales | Cubicin |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 91 | 320 | 290 | 969
Operating Segments | Total Pharmaceutical segment sales | Primaxin |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 73 | 77 | 206 | 231
Operating Segments | Total Pharmaceutical segment sales | Remicade |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 214 | 311 | 651 | 999
Operating Segments | Total Pharmaceutical segment sales | Simponi |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 219 | 193 | 602 | 581
Operating Segments | Total Pharmaceutical segment sales | Keytruda |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 1,047 | 356 | 2,512 | 919
Operating Segments | Total Pharmaceutical segment sales | Emend |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 137 | 137 | 413 | 405
Operating Segments | Total Pharmaceutical segment sales | Temodar |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 68 | 78 | 198 | 216
Operating Segments | Total Pharmaceutical segment sales | Singulair |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 161 | 239 | 550 | 705
Operating Segments | Total Pharmaceutical segment sales | Nasonex |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 42 | 94 | 266 | 425
Operating Segments | Total Pharmaceutical segment sales | Dulera |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 59 | 97 | 210 | 331
Operating Segments | Total Pharmaceutical segment sales | Cozaar/Hyzaar |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 128 | 131 | 360 | 389
Operating Segments | Total Pharmaceutical segment sales | Arcoxia |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 80 | 114 | 272 | 342
Operating Segments | Total Pharmaceutical segment sales | Fosamax |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 53 | 68 | 180 | 217
Operating Segments | Total Pharmaceutical segment sales | Gardasil/Gardasil 9 |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 675 | 860 | 1,675 | 1,631
Operating Segments | Total Pharmaceutical segment sales | ProQuad/M-M-R II/Varivax |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 519 | 496 | 1,273 | 1,236
Operating Segments | Total Pharmaceutical segment sales | Pneumovax 23 |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 229 | 175 | 558 | 403
Operating Segments | Total Pharmaceutical segment sales | Zostavax |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 234 | 190 | 547 | 464
Operating Segments | Total Pharmaceutical segment sales | RotaTeq |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 179 | 171 | 525 | 489
Operating Segments | Total Pharmaceutical segment sales | Other Pharmaceutical |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 1,013 | 1,191 | 3,172 | 3,398
Operating Segments | Other segment sales |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | 1,100 | 977 | 3,188 | 2,862
Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales |  | $ 69 | $ 116 | $ 400 | $ 583

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_CorticotropinmarketingrightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_TemodarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_DuleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_FosamaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ZostavaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |